Alpha-1 Proteinase Inhibitor Deficiency
Links shared publicly online about this topic
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency
news-medical.net — “Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled t” View full resource at news-medical.net
Most Recently Shared on February 6, 2010 at 4:52 am By:
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficienc... http://bit.ly/9T7yWx
News Article : FDA Approves New Alpha1-Proteinase Inhibitor
ashp.org — “News Article : FDA Approves New Alpha1-Proteinase Inhibitor” View full resource at ashp.org
Most Recently Shared on July 7, 2010 at 1:01 pm By:
FDA Approves New Alpha1-Proteinase Inhibitor http://bit.ly/9jj4mW via @YoTwits
Glassia approved for treating alpha 1 antitrypsin deficiency - ONA
oncologynurseadvisor.com — “Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).” View full resource at oncologynurseadvisor.com
Most Recently Shared on July 6, 2010 at 3:53 pm By:
OncologyNurseAdvisor Nursing, Medical Education, Medical Publisher, and Oncology
Glassia approved for treating alpha 1 antitrypsin deficiency http://goo.gl/fb/xUQkp
Glassia approved for treating alpha 1 antitrypsin deficiency - MPR
empr.com — “Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).” View full resource at empr.com
Most Recently Shared on July 6, 2010 at 3:33 pm By:
MPR News: Glassia approved for treating alpha 1 antitrypsin deficiency: Kamada announced that the FDA has approved... http://bit.ly/bedZ9o
Kamada Wins FDA Approval for Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency
drugs.com — “Glassia (alpha1-proteinase inhibitor (human)) is used to treat Alpha 1 deficiency. Includes Glassia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 7, 2010 at 9:27 am By:
FDA Approves Glassia - a New Liquid, Ready-to-Use Treatment for Alpha-1 Antitrypsin Deficiency - http://bit.ly/bpOUdG
Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin deficiency - MPR
empr.com — “Talecris Biotherapeutics was granted orphan drug designation by the FDA for the development of an aerosol formulation of alpha1-proteinease inhibitor to treat congenital alpha1-antitrypsin (AAT) deficiency.” View full resource at empr.com
Most Recently Shared on February 8, 2010 at 5:29 pm By:
MPR News: Orphan drug designation granted for aerosolized alpha1-proteinease inhibitor for alpha1-antitrypsin defi... http://bit.ly/9gpJZZ
Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency - MPR
empr.com — “The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) deficiency.” View full resource at empr.com
Most Recently Shared on November 15, 2009 at 9:15 pm By:
Concentrated Prolastin-C approved for alpha1-antitrypsin (AAT) deficiency ... http://cli.gs/S678E
Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss Of Lung Tissue In Patients With Deficiency-related Emphysema
medicalnewstoday.com — “Talecris Biotherapeutics (Nasdaq: TLCR) announced the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) signif” View full resource at medicalnewstoday.com
Most Recently Shared on November 16, 2010 at 2:06 pm By:
MNT Pharma News Pharma and Health News
Integrated Analysis Demonstrates Alpha(1)-Augmentation Therapy Significantly Reduces Loss Of Lung Tissue In Patients W... http://mnt.to/3MDy
BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA
news-medical.net — “BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA" [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.” View full resource at news-medical.net
Most Recently Shared on October 13, 2010 at 10:05 am By:
BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA: BioRx, a specialty pharmacy company,... http://bit.ly/9n3jKH
Talecris Biotherapeutics Receives FDA Approval for Prolastin-C
drugs.com — “Prolastin-C (Alpha1-Proteinase Inhibitor [Human]) is used to treat Alpha-1 Proteinase Inhibitor Deficiency. Includes Prolastin-C side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 19, 2009 at 11:25 pm By:
Talecris Biotherapeutics Receives FDA Approval for Prolastin-C - http://bit.ly/5wST9
Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN®
medicalnewstoday.com — “Talecris Biotherapeutics (Nasdaq: TLCR) announced the publication of results from a study showing that PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN&r” View full resource at medicalnewstoday.com
Most Recently Shared on October 22, 2010 at 6:05 pm By:
MNT Gastrointestinal Health News
Talecris Biotherapeutics Study Demonstrates PROLASTIN®-C Is As Effective As PROLASTIN® http://mnt.to/3LCv #gastrointestinal
Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal
news-medical.net — “Talecris Biotherapeutics today announced the publication of results from a study showing that PROLASTIN-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as PROLASTIN (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 protein in patients with alpha1-antitrypsin (AAT) deficiency.” View full resource at news-medical.net
Most Recently Shared on October 22, 2010 at 9:34 am By:
Medicare News: Talecris announces publication of PROLASTIN-C study results for AAT deficiency in BML journal: Tale... http://bit.ly/9sPgSI
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal
news-medical.net — “Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.” View full resource at news-medical.net
Most Recently Shared on November 15, 2010 at 2:13 pm By:
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal: Talecris Biot... http://bit.ly/c6hMtu
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal
news-medical.net — “Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1)-Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.” View full resource at news-medical.net
Most Recently Shared on November 15, 2010 at 12:46 pm By:
Talecris announces publication of A1PI studies for AAT deficiency in Respiratory Research journal: Talecris Biot... http://bit.ly/9AKYoZ
Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency
news-medical.net — “Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of d” View full resource at news-medical.net
Most Recently Shared on December 10, 2010 at 9:34 am By:
Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency: Talecr... http://bit.ly/ep6YlX
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
News-Medical.Net
Medical News from Around the World
-
Hosp Pharmacy Safety
hospital pharmacy safety, medication error abatement, USP 797, Joint Commission, NIOSH, bar coding, TPN, compounders, IV admixture, ASHP, PharmD
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
Advertisement
